[1]闫登科,陶　丽,郝　洁,等.内质网应激对肝癌细胞硼替佐米耐药性的影响[J].新乡医学院学报,2021,38(2):106-111.[doi:10.7683/xxyxyxb.2021.02.002]
　YAN Dengke,TAO Li,HAO Jie,et al.Effect of endoplasmic reticulum stress on the resistance of hepatocellular carcinoma cells to bortezomib[J].Journal of Xinxiang Medical University,2021,38(2):106-111.[doi:10.7683/xxyxyxb.2021.02.002]
点击复制

内质网应激对肝癌细胞硼替佐米耐药性的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年2
页码:
106-111
栏目:
基础研究
出版日期:
2021-02-05

文章信息/Info

Title:
Effect of endoplasmic reticulum stress on the resistance of hepatocellular carcinoma cells to bortezomib
作者:
闫登科1; 陶　丽2; 郝　洁3; 黄瑞娜1; 钟加滕4
（1.平顶山第一人民医院消化内二科，河南　平顶山　467000；2.郑州大学附属肿瘤医院消化内科，河南　郑州　450000；3.新乡医学院第一附属医院感染疾病科，河南　卫辉　453100；4.新乡医学院基础医学院病理学教研室，河南　新乡453003）
Author(s):
YAN Dengke1; TAO Li2; HAO Jie3; HUANG Ruina1; ZHONG Jiateng4
(1.Department of Gastroenterology,the First People′s Hospital of Pingdingshan,Pingdingshan 467000,Henan Province,China2.Department of Gastroenterology,Cancer Hospital Affiliated to Zhengzhou University,Zhengzhou 450000,Henan Province,China3.Department of Infectious Disease,the First Affiliated Hospital of Xinxiang Medical University,Weihui 453100,Henan Province,China4.Department of Pathology,Basic Medical College,Xinxiang Medical University,Xinxiang 453003,Henan Province,China)
关键词:
肝癌; 内质网应激; 硼替佐米; 细胞增殖; 细胞凋亡; 耐药性
Keywords:
hepatocellular carcinomaendoplasmic reticulum stressbortezomibcell proliferationcell apoptosisdrug tolerance
分类号:
R735.7
DOI:
10.7683/xxyxyxb.2021.02.002
文献标志码:
A
摘要:
目的　探讨内质网应激对肝癌细胞硼替佐米耐药性的影响。方法　将对数生长期HepG2和HuH7细胞分别分为0、5、10、15、20、30 nmol·L-1硼替佐米组，采用细胞计数试剂盒（CCK-8）检测硼替佐米干预24 h时各组细胞存活率及干预24、48、72、96 h 时细胞增殖率。将对数生长期HepG2和HuH7细胞分别分为0、10、15 nmol·L-1硼替佐米组，采用Western blot法检测HepG2和HuH7细胞中凋亡相关蛋白切割片段的半胱氨酸蛋白酶-3（cleaved caspase-3）和内质网应激相关蛋白葡萄糖调节蛋白78（GRP78）、磷酸化真核翻译起始因子2α（P-eIF-2α）、激活转录因子4 （ATF4）的表达。构建对硼替佐米耐药的HepG2细胞株（HepG2/Bort细胞），通过抑制生长曲线计算细胞的半抑制浓度（IC50），并计算细胞耐药指数（RI）。将HepG2/Bort细胞分为对照组、硼替佐米组（给予15 nmol·L-1硼替佐米干预）、硼替佐米+4-苯基丁酸（4-PBA）组（给予15 nmol·L-1硼替佐米和8 mmol·L-1 4-PBA干预）、硼替佐米+牛磺脱氧胆酸（TUDCA）组（给予15 nmol·L-1硼替佐米和1 mmol·L-1 TUDCA干预），药物作用24 h后，采用CCK-8法检测HepG2/Bort细胞存活率，采用Western blot法检测HepG2/Bort细胞中凋亡相关蛋白cleaved caspase-3和内质网应激相关蛋白GRP78、p-eIF-2α、ATF4的表达。结果　硼替佐米干预24 h后，5、10、15、20、30 nmol·L-1硼替佐米组HepG2和HuH7细胞存活率均显著低于0 nmol·L-1硼替佐米组（P＜0.05）。硼替佐米干预0、24 h时，5 nmol·L-1硼替佐米组与0 nmol·L-1硼替佐米组HepG2和HuH7细胞增殖率比较差异无统计学意义（P＞0.05）；硼替佐米干预48、72、96 h时，5 nmol·L-1硼替佐米组HepG2和HuH7细胞增殖率显著低于0 nmol·L-1硼替佐米组（P＜0.05）。干预24 h后，10、15 nmol·L-1硼替佐米组HepG2和HuH7细胞内cleaved caspase-3表达显著高于0 nmol·L-1硼替佐米组（P＜0.05）。HepG2/Bort细胞和HepG2细胞对硼替佐米的IC50分别为122.36、13.23 nmol·L-1，HepG2/Bort细胞对硼替佐米的RI为9.25。HepG2/Bort细胞中GRP78、p-eIF-2α、ATF4蛋白表达量显著高于HepG2细胞（P＜0.05）。硼替佐米组HepG2/Bort细胞存活率显著低于对照组（P＜0.05），硼替佐米+4-PBA组和硼替佐米+TUDCA组HepG2/Bort细胞存活率显著低于硼替佐米组（P＜0.05）。硼替佐米组HepG2/Bort细胞中cleaved caspase-3相对表达量显著高于对照组（P＜0.05），硼替佐米+4-PBA组和硼替佐米+TUDCA组HepG2/Bort细胞中cleaved caspase-3相对表达量显著高于硼替佐米组（P＜0.05）。结论　硼替佐米可以抑制肝癌细胞增殖，并诱导其凋亡；内质网应激抑制剂可以提高HepG2/Bort细胞对硼替佐米的敏感性，本研究为临床克服肝癌耐药提供了新的治疗策略。
Abstract:
Objective　To investigate the effect of endoplasmic reticulum stress on the resistance of hepatocellular carcinoma cells to bortezomib.Methods　　The HepG2 and Huh7 cells in logarithmic growth phase were divided into 0,5,10,15,20 and 30 nmol·L-1 bortezomib groups.The cell survival rate after 24 hours of bortezomib intervention and the cell proliferation rate after 24,48,72 and 96 hours of bortezomib intervention were detected by cell counting kit-8 (CCK-8).The HepG2 and Huh7 cells in logarithmic growth phase were divided into 0,10 and 15 nmol·L-1 bortezomib groups.The expressions of apoptosis related protein cleaved cysteinyl aspartate specific proteinase(cleaved caspase-3) and endoplasmic reticulum stress related proteins glucose regulated protein 78 (GRP78),Phosphorylated eukaryotic initiation factor-2α (P-eIF-2α),activating transcription factor 4 (ATF4) in HepG2 and Huh7 cells were detected by Western blot method.The bortezomib resistant HepG2 cell line (HepG2/Bort cells) were constructed,the 50% inhibiting concentration (IC50) and the resistance index (RI) were calculated by inhibition growth curve.The HepG2/Bort cells were divided into control group,bortezomib group (The cells were intervened with 15 nmol·L-1 bortezomib),bortezomib+4-phenylbutyric acid(4-PBA) group (The cells were intervened with 15 nmol·L-1 bortezomib and 8 mmol·L-1 4-PBA),bortezomib+tauroursodeoxy cholic acid(TUDCA) group (The cells were intervened with 15 nmol·L-1 bortezomib and 1 mmol·L-1 TUDCA).After 24 hours of drug treatment,the survival rate of HepG2/Bort cells was detected by CCK-8,and the expression of apoptosis related protein cleaved caspase-3 and endoplasmic reticulum stress-related protein GRP78,P-eIF-2α and ATF4 in HepG2/Bort cells were detected by Western blot method.Results　The survival rates of HepG2 and Huh7 cells in 5,10,15,20 and 30 nmol·L-1 bortezomib group were significantly lower than those in 0 nmol·L-1 bortezomib group after 24 hours of bortezomib intervention (P＜0.05).There was no significant difference in the proliferation rate of HepG2 and Huh7 cells between 0 nmol·L-1 bortezomib group and 5 nmol·L-1 bortezomib group after 0 and 24 hours of bortezomib intervention (P＞0.05).After 48,72 and 96 hours of bortezomib intervention,the proliferation rates of HepG2 and Huh7 cells in 5 nmol·L-1 bortezomib group were significantly lower than those in 0 nmol·L-1 bortezomib group (P＜0.05).After 24 hours of intervention,the expression of cleaved caspase-3 in HepG2 and Huh7 cells in 10 and 15 nmol·L-1 bortezomib groups was significantly higher than that in 0 nmol·L-1 bortezomib group (P＜0.05).The IC50 of HepG2/Bort cells and HepG2 cells to bortezomib was 122.36 and 13.23 nmol·L-1,respectively,and the RI of HepG2/Bort cells to bortezomib was 9.25.The expressions of GRP78,P-eIF-2α and ATF4 protein in HepG2/Bort cells were significantly higher than those in HepG2 cells (P＜0.05).The survival rate of HepG2/Bort cells in the bortezomib group was significantly lower than that in the control group (P＜0.05),and the survival rate of HepG2/Bort cells in the bortezomib+4-PBA group and bortezomib+TUDCA group was significantly lower than that in the bortezomib group (P＜0.05).The relative expression of cleaved caspase-3 in HepG2/Bort cells in the bortezomib group was significantly higher than that in the control group (P＜0.05),and the relative expression of cleaved caspase-3 in HepG2/Bort cells in the bortezomib+4-PBA group and bortezomib+TUDCA group was significantly higher than that in the bortezomib group (P＜0.05).Conclusion　Bortezomib can inhibit the proliferation and induce the apoptosis of hepatoma carcinoma cells.Endoplasmic reticulum stress inhibitor can improve the sensitivity of HepG2/Bort cells to bortezomib.This study provides a new treatment strategy for overcoming drug resistance of liver cancer.

参考文献/References:

［1］　OAKES S A,PAPA F R.The role of endoplasmic reticulum stress in human pathology［J］.Annu Rev Pathol,2015,10(1):173-194.
［2］　WANG M,KAUFMAN R J.The impact of the endoplasmic reticulum protein-folding environment on cancer development［J］.Nat Rev Cancer,2014,14(9):581-597.
［3］　STEFAN C J.Building ER-PM contacts:keeping calm and ready on alarm［J］.Curr Opin Cell Boil,2018,53(1):1-8.
［4］　COHEN S,VALM A M,LIPPINCOTT-SCHWARTZ J.Interacting organelles［J］.Curr Opin Cell Biol,2018,53(1):84-91.
［5］　WILHELM L P,WENDLING C,VEDIE B,et al.STARD3 mediates endoplasmic reticulum-to-endosome cholesterol transport at membrane contact sites［J］.EMBO J,2017,36(10):1412-1433.
［6］　HENNE W M,ZHU L,BALOGI Z,et al.Mdm1/Snx13 is a novel ER-endolysosomal interorganelle tethering protein［J］.J Cell Biol,2015,210(4):541-551.
［7］　YOO Y S,HAN H G,JEON Y J.Unfolded protein response of the endoplasmic reticulum in tumor progression and immunogenicity［J］.Oxid Med Cell Longev,2017,2017:2969271.
［8］　WANG M,KAUFMAN R J.Protein misfolding in the endoplasmic reticulum as a conduit to human disease［J］.Nature,2016,529(7586):326-335.
［9］　EL-SERAG H B.Hepatocellular carcinoma［J］.N Engl J Med,2011,365(12):1118-1127.
［10］　DENG G L,ZENG S,SHEN H.Chemotherapy and target therapy for hepatocellular carcinoma:new advances and challenges［J］.World J Hepatol,2015,7(5):787-798.
［11］　CHEN D,FREZZA M,SCHMITT S,et al.Bortezomib as the first proteasome inhibitor anticancer drug:current status and future perspectives［J］.Curr Cancer Drug Targets,2011,11(3):239-253.
［12］　HOCHSTRASSER M.Ubiquitin,proteasomes,and the regulation of intracellular protein degradation［J］.Curr Opin Cell Biol,1995,7(2):215-223.
［13］　ACCARDI F,TOSCANI D,BOLZONI M,et al.Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment:impact on myeloma-induced alterations of bone remodeling［J］.Biomed Res Int,2015,2015:172458.
［14］　KIM H J,HAN Y S,LEE J H,et al.Casein kinase 2α enhances 5-fluorouracil resistance in colorectal cancer cells by inhibiting endoplasmic reticulum stress［J］.Anticancer Res,2020,40(3):1419-1426.
［15］　TANG J Y,OU-YANG F,HOU M F,et al.Oxidative stress-modulating drugs have preferential anticancer effects:involving the regulation of apoptosis,DNA damage,endoplasmic reticulum stress,autophagy,metabolism,and migration［J］.Semin Cancer Biol,2019,58:109-117.

相似文献/References:

[1]王克霞,张荣波,唐小龙,等.肝细胞性肝癌与乙型肝炎病毒感染相关性的研究[J].新乡医学院学报,1997,14(03):281.
[2]杨瑞民,张凯,李玉侠,等.巨块型肝癌肝动脉栓塞后无水酒精注射疗效观察[J].新乡医学院学报,1997,14(04):382.
[3]甄艳华,杨利霞.肝癌患者肝动脉血流动力学的彩色多普勒研究[J].新乡医学院学报,2008,25(01):062.
[4]沈洁,阮健,郑航,等.ZD6474对肝癌HepG2细胞的抑制作用[J].新乡医学院学报,2010,27(03):234.
[5]黄长山,余伟,王云检,等.外科Apgar评分在肝癌术后并发症预测中的应用 TitleFilter('chTitle');[J].新乡医学院学报,2010,27(04):365.
[6]孙春伟,吴广银.哺乳动物雷帕霉素靶蛋白对肝癌细胞系Hep3B中侧群细胞的影响[J].新乡医学院学报,2011,28(03):307.
[7]王　雷１,王煜霞２,薛会朝１. 肝癌患者肿瘤坏死因子α和白细胞介素８水平变化及其与临床病理特征的关系[J].新乡医学院学报,2015,32(08):735.
[8]罗羽田,李世朋,徐红伟,等.铁死亡在肝癌中的调控机制及作用研究进展[J].新乡医学院学报,2021,38(1):091.[doi:10.7683/xxyxyxb.2021.01.020]
[9]王政强,韩锋博.肝癌切除术联合肝动脉化疗栓塞术治疗中晚期肝癌疗效观察[J].新乡医学院学报,2021,38(10):957.[doi:10.7683/xxyxyxb.2021.10.012]
　WANG Zhengqiang,HAN Fengbo.Effect of hepatectomy combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced liver cancer[J].Journal of Xinxiang Medical University,2021,38(2):957.[doi:10.7683/xxyxyxb.2021.10.012]
[10]王二辉,王　亚,翟德胜,等.大气细颗粒物暴露致雄性生殖功能损伤研究进展[J].新乡医学院学报,2018,35(11):1036.[doi:10.7683/xxyxyxb.2018.11.023]
　N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(2):1036.[doi:10.7683/xxyxyxb.2018.11.023]

更新日期/Last Update: 2021-02-05